NeurOp, Inc. is a clinical-stage biotechnology company developing medicines for CNS disorders including pain, stroke, subarachnoid hemorrhage and treatment-resistant depression.
Latest News
NeurOp Announces Positive Topline Data from Phase 1 Studies for Lead Candidate NP10679 for CNS Disorders
Our Science
Our compounds are designed to target various subunits of N-methyl-D-aspartate (NMDA) receptors.
About Us
Our expertise in a critical signaling pathway in the central nervous system is leading to promising drug compounds.